Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · Real-Time Price · USD
5.88
-0.17 (-2.81%)
Jul 20, 2026, 4:00 PM EDT - Market closed
Gyre Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -3.71 | 9.88 | 17.9 | -85.48 | 4.31 | -87.93 |
Depreciation & Amortization | 2.62 | 2.48 | 1.55 | 1.07 | 1.09 | 0.29 |
Stock-Based Compensation | 9.23 | 7.16 | 0.83 | 7.28 | 13.37 | 3.41 |
Other Adjustments | -0.04 | -2.93 | -8.23 | 95.59 | -0.29 | - |
Change in Receivables | -3 | -11.95 | -9.29 | 1.3 | -7.92 | 1.5 |
Changes in Inventories | -3.11 | -3.63 | -2.14 | 1.75 | -0.88 | - |
Changes in Accounts Payable | 0.14 | 0.01 | -0.25 | 0.19 | -0.11 | 0.5 |
Changes in Accrued Expenses | -2.81 | 0.95 | -1.5 | 1.45 | 1.91 | -3.68 |
Changes in Income Taxes Payable | 2.45 | 0.04 | -2.17 | 3 | -1.34 | - |
Changes in Unearned Revenue | - | - | - | - | - | -1.75 |
Changes in Other Operating Activities | 4.42 | -1 | -0.36 | -0.23 | 0.54 | 3.92 |
Operating Cash Flow | 4.32 | 1.01 | -3.64 | 25.89 | 10.68 | -83.76 |
Operating Cash Flow Growth | - | - | - | 142.50% | - | - |
Capital Expenditures | -1.25 | -1.19 | -2.32 | -8.52 | -4.99 | -0.84 |
Sale of Property, Plant & Equipment | 0.04 | 0.03 | 0.4 | 0.66 | - | - |
Purchases of Intangible Assets | -0.04 | -0.73 | -0.81 | -0.07 | -0.01 | - |
Purchases of Investments | -18.56 | -14.01 | -15.47 | -15.74 | -7.48 | - |
Proceeds from Sale of Investments | 14.31 | 15.43 | - | - | - | 49.03 |
Other Investing Activities | - | - | -1.69 | 3.9 | -1.33 | - |
Investing Cash Flow | -5.5 | -0.47 | -19.88 | -19.76 | -13.81 | 48.19 |
Issuance of Common Stock | 1.42 | 25.87 | 2.64 | - | - | 49.55 |
Net Common Stock Issued (Repurchased) | 1.42 | 25.87 | 2.64 | - | - | 49.55 |
Issuance of Preferred Stock | - | - | - | 2.5 | - | - |
Net Preferred Stock Issued (Repurchased) | - | - | - | 2.5 | - | - |
Other Financing Activities | -1.37 | -1.49 | -0.54 | - | - | - |
Financing Cash Flow | 23.06 | 24.38 | 2.1 | 2.5 | - | 49.55 |
Effect of Exchange Rate Changes on Cash and Cash Equivalents | 0.58 | 0.34 | -0.27 | -0.3 | -1.89 | - |
Net Cash Flow | 22.46 | 25.26 | -21.7 | 8.33 | -5.03 | 13.99 |
Free Cash Flow | 3.07 | -0.18 | -5.96 | 17.38 | 5.69 | -84.59 |
Free Cash Flow Growth | - | - | - | 205.25% | - | - |
FCF Margin | 2.63% | -0.15% | -5.63% | 15.32% | 5.56% | -1152.82% |
Free Cash Flow Per Share | 0.03 | -0.00 | -0.06 | 0.26 | 0.08 | -1.27 |
Levered Free Cash Flow | -3.89 | 2.69 | 4.92 | -94.22 | -1.47 | -89.49 |
Unlevered Free Cash Flow | 3.4 | 5.53 | 5.29 | -75.96 | 0.44 | -89.46 |